Follow
Prson Gautam, PhD
Prson Gautam, PhD
Visiting Researcher, Institute for Molecular Medicine Finland, University of Helsinki
Verified email at helsinki.fi
Title
Cited by
Cited by
Year
Endothelial destabilization by angiopoietin-2 via integrin β1 activation
L Hakanpaa, T Sipila, VM Leppanen, P Gautam, H Nurmi, G Jacquemet, ...
Nature communications 6 (1), 5962, 2015
3042015
Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression
TK Hayes, NF Neel, C Hu, P Gautam, M Chenard, B Long, M Aziz, ...
Cancer cell 29 (1), 75-89, 2016
2622016
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ...
Cancer discovery 10 (1), 104-123, 2020
1882020
KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism
AV Vaseva, DR Blake, TSK Gilbert, S Ng, G Hostetter, SH Azam, ...
Cancer cell 34 (5), 807-822. e7, 2018
1772018
Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions
J Tang, B Ravikumar, Z Alam, A Rebane, M Vähä-Koskela, G Peddinti, ...
Cell chemical biology 25 (2), 224-229. e2, 2018
1562018
Prediction of drug combination effects with a minimal set of experiments
A Ianevski, AK Giri, P Gautam, A Kononov, S Potdar, J Saarela, ...
Nature machine intelligence 1 (12), 568-577, 2019
1452019
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
C Nepal, CJ O'Rourke, DVNP Oliveira, A Taranta, S Shema, P Gautam, ...
Hepatology 68 (3), 949-963, 2018
1342018
Risk of handling paper currency in circulation chances of potential bacterial transmittance
J Lamichhane, S Adhikary, P Gautam, R Maharjan, B Dhakal
Nepal Journal of Science and Technology 10, 161-166, 2009
1112009
Consistency in drug response profiling
JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ...
Nature 540 (7631), E5-E6, 2016
1012016
Bioluminescent, nonlytic, real-time cell viability assay and use in inhibitor screening
SJ Duellman, W Zhou, P Meisenheimer, G Vidugiris, JJ Cali, P Gautam, ...
Assay and drug development technologies 13 (8), 456-465, 2015
1012015
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
H Julkunen, A Cichonska, P Gautam, S Szedmak, J Douat, T Pahikkala, ...
Nature communications 11 (1), 6136, 2020
1002020
Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers
I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ...
Cell reports 31 (11), 2020
922020
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
P Gautam, L Karhinen, A Szwajda, SK Jha, B Yadav, T Aittokallio, ...
Molecular cancer 15, 1-16, 2016
762016
Rational polypharmacology: systematically identifying and engaging multiple drug targets to promote axon growth
H Al-Ali, DH Lee, MC Danzi, H Nassif, P Gautam, K Wennerberg, ...
ACS chemical biology 10 (8), 1939-1951, 2015
702015
Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function
R Tuuminen, AI Nykänen, P Saharinen, P Gautam, MAI Keränen, ...
American Journal of Transplantation 13 (8), 2019-2034, 2013
572013
Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors
CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ...
Cancer research 82 (4), 586-598, 2022
472022
Phenotypic screening combined with machine learning for efficient identification of breast cancer-selective therapeutic targets
P Gautam, A Jaiswal, T Aittokallio, H Al-Ali, K Wennerberg
Cell chemical biology 26 (7), 970-979. e4, 2019
462019
CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis
A Laine, SG Nagelli, C Farrington, U Butt, AN Cvrljevic, JP Vainonen, ...
Cancer research 81 (16), 4319-4331, 2021
452021
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
A Ianevski, J Lahtela, KK Javarappa, P Sergeev, BR Ghimire, P Gautam, ...
Science advances 7 (8), eabe4038, 2021
372021
Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
J Tang, P Gautam, A Gupta, L He, S Timonen, Y Akimov, W Wang, ...
NPJ systems biology and applications 5 (1), 20, 2019
372019
The system can't perform the operation now. Try again later.
Articles 1–20